EMJ Dermatology 6.1 2018

EMJ Dermatology 6.1 showcases fascinating content that will spark countless hours of intense debate, no doubt leading to further developments and breakthroughs within the field of dermatology.

Tralokinumab in the Era of Disruption in Atopic Dermatitis

Gain valuable insights from three atopic dermatitis (AD) specialists who specifically consider one of the newest systemic therapies that targets the cytokine IL-13, a key cytokine involved in the pathogenesis of AD. Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

Skin Microbiome and Acne

Marco Rocha, Thomas Dirschka, and Alison Layton discuss the current acne landscape, the potential role of the skin microbiome in acne… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

Therapies for AGA

Androgenetic alopecia (AGA) is the leading cause of hair loss in both men and women. Experts outline current and emerging therapies in the… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

Tralokinumab in Atopic Dermatitis

To discuss how biologics have disrupted clinical management of atopic dermatitis, and how tralokinumab fits into this paradigm, the EMJ sat… Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

EMJ Dermatology 6.1 2018

In this issue

Tralokinumab in the Era of Disruption in Atopic Dermatitis

Skin Microbiome and Acne

Therapies for AGA

Tralokinumab in Atopic Dermatitis

Therapy Area

About Us

EMJ Dermatology 6.1 2018

In this issue

Latest articles

Tralokinumab in the Era of Disruption in Atopic Dermatitis

Skin Microbiome and Acne

Therapies for AGA

Tralokinumab in Atopic Dermatitis